Tumor-Infiltrating Macrophages in Post-Transplant, Relapsed Classical Hodgkin Lymphoma Are Donor-Derived.
Tumor-associated inflammatory cells in classical Hodgkin lymphoma (CHL) typically outnumber the neoplastic Hodgkin/Reed-Sternberg (H/RS) cells. The composition of the inflammatory infiltrate, particularly the fraction of macrophages, has been associated with clinical behavior. Emerging work from animal models demonstrates that most tissue macrophages are maintained by a process of self-renewal under physiologic circumstances and certain inflammatory states, but the contribution from circulating monocytes may be increased in some disease states. This raises the question of the source of macrophages involved in human disease, particularly that of CHL. Patients with relapsed CHL following allogeneic bone marrow transplant (BMT) provide a unique opportunity to begin to address this issue. We identified 4 such patients in our archives. Through molecular chimerism and/or XY FISH studies, we demonstrated the DNA content in the post-BMT recurrent CHL was predominantly donor-derived, while the H/RS cells were derived from the patient. Where possible to evaluate, the cellular composition of the inflammatory infiltrate, including the percentage of macrophages, was similar to that of the original tumor. Our findings suggest that the H/RS cells themselves define the inflammatory environment. In addition, our results demonstrate that tumor-associated macrophages in CHL are predominantly derived from circulating monocytes rather than resident tissue macrophages. Given the association between tumor microenvironment and disease progression, a better understanding of macrophage recruitment to CHL may open new strategies for therapeutic intervention.
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Genevieve M
http://orcid.org/0000-0001-9274-0214
GM
Crane
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Mark A
MA
Samols
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Laura A
LA
Morsberger
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Raluca
R
Yonescu
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Michele L
ML
Thiess
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Denise A S
DA
Batista
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Yi
Y
Ning
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Kathleen H
KH
Burns
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Milena
M
Vuica-Ross
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Michael J
MJ
Borowitz
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Christopher D
CD
Gocke
Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Richard F
RF
Ambinder
Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland, United States of America.
Amy S
AS
Duffield
Science. 1976 Jun 4;192(4243):1016-8
775638
BMC Cancer. 2014 May 15;14:335
24886161
Am J Pathol. 1999 Jun;154(6):1685-91
10362793
Clin Cancer Res. 2012 Jul 15;18(14):3762-71
22645050
Immunity. 2013 Jan 24;38(1):79-91
23273845
Clin Cancer Res. 2003 Jun;9(6):2114-20
12796376
Am J Clin Pathol. 1994 Jun;101(6):761-7
8209866
Hematol Oncol. 2009 Mar;27(1):31-9
18924115
Clin Cancer Res. 2005 Feb 15;11(4):1467-73
15746048
Blood. 1999 Sep 15;94(6):2065-71
10477736
Blood. 2006 Oct 1;108(7):2280-9
16757686
Haematologica. 2008 Feb;93(2):193-200
18223287
Nature. 2011 Jun 08;475(7355):222-5
21654748
Hematology Am Soc Hematol Educ Program. 2009;:491-6
20008234
Immunity. 2013 Apr 18;38(4):792-804
23601688
Blood. 2009 Mar 19;113(12):2765-3775
19096012
N Engl J Med. 1984 Apr 26;310(17):1123-4
6369135
PLoS One. 2014 Dec 03;9(12):e114345
25470820
J Clin Oncol. 2006 Oct 1;24(28):4626-33
16954517
Blood. 2012 Oct 18;120(16):3280-7
22948049
Hum Pathol. 2013 Nov;44(11):2475-86
24029709
Immunotherapy. 2013 Oct;5(10):1075-87
24088077
J Exp Med. 2009 Feb 16;206(2):371-85
19171766
Nature. 2013 Apr 25;496(7446):445-55
23619691
Int J Cancer. 2008 Feb 15;122(4):769-76
17935139
Leuk Lymphoma. 2005 Nov;46(11):1581-91
16236613
J Exp Med. 1968 May 1;127(5):943-52
5655103
J Leukoc Biol. 1987 Nov;42(5):443-6
3316460
Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10340-5
16801531
Eur J Cancer. 2006 Apr;42(6):717-27
16520032
Am J Pathol. 2004 Mar;164(3):997-1006
14982853
Clin Cancer Res. 2013 Jul 1;19(13):3404-15
23653148
Haematologica. 2011 Feb;96(2):269-76
21071500
Am J Gastroenterol. 2008 Jun;103(6):1428-35; quiz 1436
18494836
Blood. 2000 Feb 15;95(4):1207-13
10666192
N Engl J Med. 2010 Mar 11;362(10):875-85
20220182
Cancer. 1985 Jul 15;56(2):333-8
2408733
Nature. 2015 Feb 26;518(7540):547-51
25470051
Nat Rev Immunol. 2014 Jun;14(6):392-404
24854589
Int J Cancer. 2003 Nov 1;107(2):197-201
12949794